Recombitek® Equine West Nile Virus
West Nile Virus Vaccine, Live Canarypox Vector
RECOMBITEK® Equine West Nile Virus contains a lyophilized recombinant
canarypox vectored West Nile Virus vaccine plus a sterile liquid diluent. A canarypox
vector has been modified using recombinant technology to express the desired antigens
capable of stimulating a protective immune response to West Nile Virus. After inoculation,
the vector does not multiply in the horse, but does express the protective proteins.
As a consequence, these components induce an immune status against West Nile Virus.
Safety and immunogenicity of this vaccine have been demonstrated by vaccination
and challenge tests in susceptible horses.
RECOMBITEK® WNV is recommended for the vaccination of healthy horses
as an aid in the prevention of viremia due to West Nile Virus infection.
Reconstitute the lyophilized vaccine with accompanying liquid diluent and aseptically
inject a 1 mL dose by intramuscular route. For primary vaccination, revaccinate
with a second 1 mL dose of this product 4 to 6 weeks later. Annual revaccination
with a single dose is recommended.
Store at 2-7 ° C (35-45 ° F). For the preparation and administration of the vaccine,
use sterile and antiseptic-free and/or disinfectant-free material. Burn container
and all unused contents. Contains gentamicin as a preservative. Do not vaccinate
within 21 days prior to slaughter. As with any vaccine, a hypersensitivity reaction
may occur, which may require appropriate symptomatic treatment.
Sold to veterinarians only.